Design Therapeutics, Inc. (DSGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

8.09

-0.19

(-2.24%)

As of 11:31AM EST. Market open.

Advertisement

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

Simply Wall St.
Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN)
Investors who take an interest in Design Therapeutics, Inc. ( NASDAQ:DSGN ) should definitely note that the Independent...
GlobeNewswire
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs Endothelial Corneal Dystrophy Administered as an Eye Drop; IND Expected in 2023 Advancing Myotonic Dystrophy Type-1 GeneTACTM Lead Molecules; IND Expected in 2024 Conference Call to be Held Today at 4:30pm ET CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nas
Simply Wall St.
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Advertisement